RBC Capital analyst Brian Abrahams maintained a Buy rating on Hookipa Pharma (HOOK) on April 9 and set a price target of $23.00. The company’s shares closed last Friday at $13.71.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.7% and a 47.2% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
Currently, the analyst consensus on Hookipa Pharma is a Strong Buy with an average price target of $21.50, representing a 54.0% upside. In a report issued on April 8, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
Based on Hookipa Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.16 million and GAAP net loss of $12.47 million. In comparison, last year the company earned revenue of $3.62 million and had a GAAP net loss of $10.24 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
